UN&UP Receives Another Prestigious NIH Phase II SBIR Award from the NINDS for its Novel TheraLode™ Thrombolysis Platform

Written By Guest User
 
 


We are thrilled to share that UN&UP has been awarded its largest NIH Phase II SBIR award yet from the NINDS for developing our innovative TheraLode™ thrombolysis pharmaceutical platform for acute ischemic stroke.

We want to express our gratitude to our clinical research partners, who are not only well-respected opinion leaders in their field but also strong supporters of our mission to revolutionize stroke care by enhancing the safety and effectiveness of thrombolysis treatment, enabling us to treat 10 times more stroke victims.

Our esteemed partners include Dr. Colin Derdeyn (University of Iowa), Dr. Thomas Hemmen (UCSD), Dr. Peter Panagos (Washington University), and Dr. Bruce Campbell (Royal Melbourne University).

Furthermore, we would like to extend our appreciation to Dr. Olin Mefford (Clemson University), the St. Louis BioGenerator, BioSTL, and the Missouri Technology Corporation for their invaluable contributions to this endeavor.

 
Guest User
Previous

UN&UP Featured in the St. Louis INNO Chapter of The Business Journals for Efforts to Advance Stroke Treatment
Next

NIH Selects UN&UP to present at the International BIO Conference in Boston